시장보고서
상품코드
1841565

업스트림 바이오프로세스 장비 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품 유형별, 워크플로우별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Upstream Bioprocessing Equipment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Workflow, By End-User, By Region & Competition, 2020-2030F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 185 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 업스트림 바이오프로세스 장비 시장 규모는 2024년에 295억 4,000만 달러로 평가되었으며, 예측 기간 동안 CAGR 10.67%로 2030년에는 547억 6,000만 달러에 달할 것으로 예측됩니다.

시장 개요
예측 기간 2026-2030년
시장 규모 : 2024년 295억 4,000만 달러
시장 규모 : 2030년 547억 6,000만 달러
CAGR : 2025-2030년 10.67%
급성장 부문 세포 분리
최대 시장 북미

업스트림 바이오프로세스 장비 시장은 생물학적 제제 개발의 초기 단계, 특히 세포배양 및 발효 공정에 중점을 둔 바이오의약품 제조 산업 부문을 말합니다. 여기에는 백신, 단클론항체, 호르몬, 재조합 단백질을 포함한 생물학적 제제 제조에 사용되는 살아있는 세포와 미생물의 배양에 필수적인 바이오리액터, 발효기, 세포배양 배지, 여과시스템, 혼합시스템 등의 장비가 포함됩니다.

이 시장은 바이오의약품, 맞춤의료, 바이오시밀러에 대한 전 세계적인 수요 급증에 힘입어 크게 성장할 것으로 전망됩니다. 만성질환 및 생활습관 관련 건강 문제가 증가함에 따라 효과적인 생물학적 치료제의 필요성이 더욱 절실해지고 있으며, 이에 따라 업스트림 제조 역량에 대한 투자가 촉진되고 있습니다. 또한, 일회용 바이오리액터, 자동화, 연속 바이오 공정과 같은 기술 혁신은 제조 워크플로우를 간소화하고 효율성을 향상시키며, 무균 제약 환경에서 중요한 고려사항인 오염 위험을 감소시킵니다.

신흥국의 위탁생산 기관과 바이오제약 기업의 확대도 낮은 운영 비용으로 첨단 제조 인프라를 이용할 수 있게함으로써 시장 성장을 촉진하고 있습니다. 또한, 바이오의약품 연구 및 바이오 제조 인프라 개발에 대한 정부 지원은 산업 확장을 더욱 촉진하고 있습니다. 또한, 스테인리스 스틸과 일회용 부품을 결합한 하이브리드 바이오프로세싱 시스템의 채택이 증가하고 있으며, 이는 더 높은 유연성과 비용 효율성을 제공함으로써 기존 기업과 신생 기업 모두에게 어필하고 있습니다.

제품 품질과 공정 표준화에 대한 규제 강화와 함께 공정의 확장성 및 강화에 대한 관심이 높아짐에 따라 기업들은 업스트림 공정 능력의 업그레이드를 위해 노력할 것으로 예상됩니다. 생물학적 제제 파이프라인이 확장되고 더 복잡한 분자가 개발됨에 따라 업스트림 바이오프로세스 장비는 높은 수율과 재현성 있는 생산을 보장하는 데 점점 더 중요한 역할을 하게 될 것입니다. 그 결과, 업스트림 바이오프로세스 장비 시장은 기술 발전, 바이오의약품 생산량 증가, 비용 효율적이고 확장 가능한 바이오 제조 솔루션에 대한 수요 등으로 인해 선진국과 신흥국 시장 모두에서 강력한 성장세를 보일 것으로 예상됩니다.

주요 시장 촉진요인

바이오의약품 수요 증가

주요 시장 과제

높은 설비 투자 및 운영 비용

주요 시장 동향

업스트림 바이오프로세스 장비의 일회용 기술 통합

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 업스트림 바이오프로세스 장비 시장 전망

  • 시장 규모 및 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 유형별(바이오리액터/발효조, 세포배양 용기, 여과 시스템, 혼합 시스템, 샘플링 시스템, 기타)
    • 워크플로우별(배지 조제, 세포배양, 세포 분리)
    • 최종사용자별(제약·바이오테크놀러지 기업, 수탁제조기관, 학술조사기관)
    • 지역별(북미, 유럽, 남미, 중동 및 아프리카, 아시아태평양)
  • 기업별(2024)
  • 시장 맵

제6장 북미의 업스트림 바이오프로세스 장비 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 북미 : 국가별 분석
    • 미국
    • 캐나다
    • 멕시코

제7장 유럽의 업스트림 바이오프로세스 장비 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 유럽 : 국가별 분석
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인

제8장 아시아태평양의 업스트림 바이오프로세스 장비 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주

제9장 중동 및 아프리카의 업스트림 바이오프로세스 장비 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 중동 및 아프리카 : 국가별 분석
    • 사우디아라비아
    • 아랍에미리트
    • 남아프리카공화국

제10장 남미의 업스트림 바이오프로세스 장비 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 남미 : 국가별 분석
    • 브라질
    • 콜롬비아
    • 아르헨티나

제11장 시장 역학

  • 성장 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 인수합병
  • 제품 출시
  • 최근 동향

제13장 기업 개요

  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Merck KGaA
  • Eppendorf AG
  • ZETA GmbH
  • PBS Biotech, Inc.
  • Thermogenics Inc.
  • Pierre Guerin Technologies
  • Bioengineering AG

제14장 전략적 제안

제15장 조사 회사 소개 및 면책사항

KSM

Global Upstream Bioprocessing Equipment Market was valued at USD 29.54 billion in 2024 and is expected to reach USD 54.76 billion by 2030 with a CAGR of 10.67% during the forecast period.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 29.54 Billion
Market Size 2030USD 54.76 Billion
CAGR 2025-203010.67%
Fastest Growing SegmentCell Separation
Largest MarketNorth America

The Upstream Bioprocessing Equipment Market refers to the segment of the biopharmaceutical manufacturing industry that focuses on the initial phases of biological product development, particularly cell culture and fermentation processes. This includes equipment such as bioreactors, fermenters, cell culture media, filtration systems, and mixing systems that are essential for cultivating living cells or microorganisms used to produce biologics, including vaccines, monoclonal antibodies, hormones, and recombinant proteins.

The market is poised for significant growth driven by the surging global demand for biopharmaceuticals, personalized medicine, and biosimilars. As the prevalence of chronic diseases and lifestyle-related health issues increases, the need for effective biologic therapies is becoming more urgent, propelling investment in upstream manufacturing capacities. Furthermore, technological innovations such as single-use bioreactors, automation, and continuous bioprocessing are streamlining production workflows, enhancing efficiency, and reducing contamination risks, which are vital considerations in sterile pharmaceutical environments.

The expansion of contract manufacturing organizations and biopharmaceutical companies in emerging economies is also fueling market growth by enabling access to advanced manufacturing infrastructure at lower operational costs. In addition, government support in the form of funding for biologics research and biomanufacturing infrastructure development is further stimulating industry expansion. Moreover, increased adoption of hybrid bioprocessing systems that combine stainless steel and disposable components is offering greater flexibility and cost-efficiency, appealing to both established players and startups.

The growing focus on process scalability and intensification, along with regulatory emphasis on product quality and process standardization, is expected to push companies toward upgrading their upstream processing capabilities. As biologic pipelines expand and more complex molecules are developed, upstream bioprocessing equipment will play an increasingly critical role in ensuring high-yield and reproducible production. As a result, the upstream bioprocessing equipment market is anticipated to witness robust growth across developed and developing regions, driven by technological advancements, rising biologics production, and the need for cost-effective and scalable biomanufacturing solutions.

Key Market Drivers

Rising Demand for Biopharmaceuticals

The increasing global demand for biopharmaceuticals, such as monoclonal antibodies, vaccines, and gene therapies, is a primary driver for the Upstream Bioprocessing Equipment Market. The surge in chronic diseases like cancer, diabetes, and autoimmune disorders, coupled with an aging population, has escalated the need for advanced biologics. Upstream bioprocessing equipment, including bioreactors and cell culture systems, is critical for producing these complex therapies at scale.

Governments and healthcare organizations worldwide are prioritizing biopharmaceutical development to address public health challenges, particularly following global health crises like the COVID-19 pandemic, which highlighted the urgency for rapid vaccine production. The shift toward personalized medicine and targeted therapies further amplifies the demand for flexible and scalable bioprocessing solutions. Equipment such as single-use bioreactors enables manufacturers to meet diverse production needs while minimizing contamination risks.

Additionally, emerging markets in Asia-Pacific and Latin America are witnessing increased investments in biopharmaceutical infrastructure, driven by rising healthcare expenditures and growing prevalence of chronic conditions. The ability of upstream equipment to support high-yield cell cultures and recombinant protein production is vital for meeting this demand. As biopharmaceutical companies expand their pipelines to include novel biologics, the Upstream Bioprocessing Equipment Market is poised for sustained growth, fueled by the need for efficient, high-quality production systems that align with stringent regulatory standards and support global health initiatives.

In 2023, global biopharmaceutical production reached 1.2 million liters, with monoclonal antibodies accounting for 45% of output, per the International Federation of Pharmaceutical Manufacturers. Upstream equipment supported 60% of this capacity, with single-use systems contributing to 25% of production. In 2022, vaccine production surged by 30% globally, with bioreactors enabling 2 billion doses, addressing 15% of global demand, particularly in Asia-Pacific, where 200 new facilities were established.

Key Market Challenges

High Capital Investment and Operational Costs

One of the most significant challenges facing the upstream bioprocessing equipment market is the high capital investment required for the installation, commissioning, and validation of biomanufacturing infrastructure. Establishing a biologics manufacturing facility equipped with upstream processing equipment such as bioreactors, centrifuges, media preparation systems, and filtration units involves substantial upfront costs, which can be a barrier for small and mid-sized enterprises. In addition to equipment procurement, expenses related to facility design, utility setup, cleanroom construction, and compliance with regulatory requirements considerably increase the financial burden.

Moreover, the cost of operation is also high due to the need for specialized labor, ongoing maintenance, and frequent calibration of equipment to maintain sterility and productivity. Companies operating in this space must also invest significantly in workforce training and certification to ensure operational proficiency and quality control. While some larger biopharmaceutical companies can absorb these costs due to their expansive budgets and economies of scale, emerging firms and startups often face difficulties in securing adequate funding.

This financial barrier may hinder innovation and delay the time-to-market for critical biologics, especially in regions where public and private investment in biomanufacturing is still limited. The high cost of implementing advanced technologies such as automation, real-time monitoring systems, and single-use components further exacerbates the challenge, particularly for firms seeking cost-efficiency in production.

As the demand for scalable and flexible production systems increases, stakeholders in the upstream bioprocessing equipment market must explore alternative funding models, government grants, and collaborative partnerships to overcome the financial constraints associated with capital investment and operational expenses.

Key Market Trends

Integration of Single-Use Technologies in Upstream Bioprocessing Equipment

The global Upstream Bioprocessing Equipment Market is witnessing a transformative shift with the rapid integration of single-use technologies in bioprocessing workflows. Single-use systems, which include bioreactors, mixers, tubing, and filtration units, are increasingly replacing traditional stainless-steel systems. This trend is particularly driven by the advantages these technologies offer in terms of operational flexibility, reduced contamination risk, and shorter turnaround time between production cycles. In research and development environments, as well as early-phase biologics manufacturing, single-use systems facilitate faster experimentation and scale-up processes without the extensive cleaning and validation requirements of reusable equipment.

Pharmaceutical and biotechnology companies are investing heavily in modular single-use platforms that enable rapid configuration and adjustment based on batch size or biologic type. These platforms allow for high levels of customization, making them suitable for the production of personalized medicines and monoclonal antibodies. Additionally, the reduced capital investment needed for single-use systems appeals to emerging biopharmaceutical firms and contract manufacturing organizations.

Environmental concerns associated with disposability are being addressed through improved material science, with manufacturers developing recyclable or biodegradable single-use components. The growing acceptance of these sustainable options is further accelerating adoption. Regulatory bodies are also becoming more familiar with single-use equipment validation protocols, contributing to their widespread market integration.

As a result, single-use technologies are transforming upstream operations by simplifying workflows, minimizing cross-contamination, and enabling rapid bioprocessing innovation, thereby contributing significantly to the growth of the Upstream Bioprocessing Equipment Market.

Key Market Players

  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Merck KGaA
  • Eppendorf AG
  • ZETA GmbH
  • PBS Biotech, Inc.
  • Thermogenics Inc.
  • Pierre Guerin Technologies
  • Bioengineering AG

Report Scope:

In this report, the Global Upstream Bioprocessing Equipment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Upstream Bioprocessing Equipment Market, By Product Type:

  • Bioreactors/Fermenters
  • Cell Culture Vessels
  • Filtration Systems
  • Mixing Systems
  • Sampling Systems
  • Others

Upstream Bioprocessing Equipment Market, By Workflow:

  • Media Preparation
  • Cell Culture
  • Cell Separation

Upstream Bioprocessing Equipment Market, By End-User:

  • Pharmaceutical and Biotechnology Companies
  • Contract Manufacturing Organizations
  • Academic and Research Institutes

Upstream Bioprocessing Equipment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Upstream Bioprocessing Equipment Market.

Available Customizations:

Global Upstream Bioprocessing Equipment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Upstream Bioprocessing Equipment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Bioreactors/Fermenters, Cell Culture Vessels, Filtration Systems, Mixing Systems, Sampling Systems, Others)
    • 5.2.2. By Workflow (Media Preparation, Cell Culture, Cell Separation)
    • 5.2.3. By End-User (Pharmaceutical and Biotechnology Companies, Contract Manufacturing Organizations, Academic and Research Institutes)
    • 5.2.4. By Region (North America, Europe, South America, Middle East & Africa, Asia Pacific)
  • 5.3. By Company (2024)
  • 5.4. Market Map

6. North America Upstream Bioprocessing Equipment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Workflow
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Upstream Bioprocessing Equipment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Workflow
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Upstream Bioprocessing Equipment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Workflow
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Upstream Bioprocessing Equipment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Workflow
        • 6.3.3.2.3. By End-User

7. Europe Upstream Bioprocessing Equipment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Workflow
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Upstream Bioprocessing Equipment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Workflow
        • 7.3.1.2.3. By End-User
    • 7.3.2. France Upstream Bioprocessing Equipment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Workflow
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Upstream Bioprocessing Equipment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Workflow
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Upstream Bioprocessing Equipment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Workflow
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Upstream Bioprocessing Equipment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Workflow
        • 7.3.5.2.3. By End-User

8. Asia Pacific Upstream Bioprocessing Equipment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Workflow
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Upstream Bioprocessing Equipment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Workflow
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Upstream Bioprocessing Equipment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Workflow
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Upstream Bioprocessing Equipment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Workflow
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Upstream Bioprocessing Equipment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Workflow
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Upstream Bioprocessing Equipment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Workflow
        • 8.3.5.2.3. By End-User

9. Middle East & Africa Upstream Bioprocessing Equipment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Workflow
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Upstream Bioprocessing Equipment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Workflow
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE Upstream Bioprocessing Equipment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Workflow
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa Upstream Bioprocessing Equipment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Workflow
        • 9.3.3.2.3. By End-User

10. South America Upstream Bioprocessing Equipment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Workflow
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Upstream Bioprocessing Equipment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Workflow
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia Upstream Bioprocessing Equipment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Workflow
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina Upstream Bioprocessing Equipment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Workflow
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends and Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Company Profiles

  • 13.1. Sartorius AG
    • 13.1.1. Business Overview
    • 13.1.2. Key Revenue and Financials
    • 13.1.3. Recent Developments
    • 13.1.4. Key Personnel
    • 13.1.5. Key Product/Services Offered
  • 13.2. Thermo Fisher Scientific Inc.
  • 13.3. Danaher Corporation
  • 13.4. Merck KGaA
  • 13.5. Eppendorf AG
  • 13.6. ZETA GmbH
  • 13.7. PBS Biotech, Inc.
  • 13.8. Thermogenics Inc.
  • 13.9. Pierre Guerin Technologies
  • 13.10. Bioengineering AG

14. Strategic Recommendations

15. About Us & Disclaimer

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제